Literature DB >> 15184594

Are MuSK antibodies the primary cause of myasthenic symptoms?

Duygu Selcen1, Taku Fukuda, Xin-Ming Shen, Andrew G Engel.   

Abstract

OBJECTIVE: To investigate the morphologic, electrophysiologic, and molecular correlates of muscle-specific tyrosine kinase-seropositive [MuSK(+)] myasthenia gravis (MG).
BACKGROUND: Anti-MuSK antibodies are detected in some of acetylcholine receptor-seronegative [AChR(-)] patients with MG with prominent facial, bulbar, and respiratory muscle involvement. The morphologic and electrophysiologic correlates of MuSK(+) MG have not been investigated to date.
METHODS: Immunohistochemistry, electron microscopy, and in vitro electrophysiology studies were performed on an intercostal muscle specimen of a patient with MuSK(+) MG and in control subjects. MUSK was directly sequenced, and the nucleotide changes were traced with allele-specific PCR in control subjects.
RESULTS: A man aged 34 years has had facial weakness since childhood and progressive bulbar and respiratory muscle weakness and intermittent diplopia since age 21 years. He has thin temporalis and masseter muscles, a high-arched palate, and an atrophic tongue. EMG shows a 36% decrement in facial muscles. His mother has similar facial features. His endplates (EPs) show no AChR or MuSK deficiency, but the amplitudes of the miniature EP potentials and currents are reduced to 35% and 55% of normal, respectively. EP ultrastructure is well preserved, but some junctional folds immunostain faintly for immunoglobulin G. Mutation analysis of MUSK reveals one rare and two common DNA polymorphisms.
CONCLUSIONS: 1) The circulating anti-muscle-specific tyrosine kinase antibodies caused neither muscle-specific tyrosine kinase nor acetylcholine receptor deficiency at the endplates; 2) the reduced intercostal miniature endplate potential and current amplitudes were not accounted for by acetylcholine receptor deficiency; 3) the faint immunoglobulin G deposits at the endplates may or may not represent anti-muscle-specific tyrosine kinase antibodies; and 4) the anti-muscle-specific tyrosine kinase antibodies may not be the primary cause of myasthenic symptoms in this patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184594     DOI: 10.1212/01.wnl.0000128048.23930.1d

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  Innervation and neuromuscular control in ageing skeletal muscle.

Authors:  Russell T Hepple; Charles L Rice
Journal:  J Physiol       Date:  2015-12-21       Impact factor: 5.182

Review 2.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

3.  Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

Authors:  Y Kawakami; M Ito; M Hirayama; K Sahashi; B Ohkawara; A Masuda; H Nishida; N Mabuchi; A G Engel; K Ohno
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

4.  Misdiagnosis of Myasthenia Gravis and Subsequent Clinical Implication: A case report and review of literature.

Authors:  Abdullah Al-Asmi; Ramachandiran Nandhagopal; P C Jacob; Arunodaya Gujjar
Journal:  Sultan Qaboos Univ Med J       Date:  2012-02-07

5.  Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction.

Authors:  Nazanin Ghazanfari; Marco Morsch; Stephen W Reddel; Simon X Liang; William D Phillips
Journal:  J Physiol       Date:  2014-05-23       Impact factor: 5.182

Review 6.  The role of complement in experimental autoimmune myasthenia gravis.

Authors:  Linda L Kusner; Henry J Kaminski
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

7.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

Review 8.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

9.  LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner.

Authors:  Bisei Ohkawara; Macarena Cabrera-Serrano; Tomohiko Nakata; Margherita Milone; Nobuyuki Asai; Kenyu Ito; Mikako Ito; Akio Masuda; Yasutomo Ito; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2013-11-13       Impact factor: 6.150

10.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.